Sachpekidis C - Search Results

1

PSMA radioligand therapy in prostate cancer: overview, latest advances and remaining challenges.

Sachpekidis C, Alberts I, Rominger A, Afshar-Oromieh A. Sachpekidis C, et al. Immunotherapy. 2019 Oct;11(15):1267-1271. doi: 10.2217/imt-2019-0146. Epub 2019 Sep 9. Immunotherapy. 2019. PMID: 31496329 No abstract available.

2

Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level.

John L, Poos AM, Brobeil A, Schinke C, Huhn S, Prokoph N, Lutz R, Wagner B, Zangari M, Tirier SM, Mallm JP, Schumacher S, Vonficht D, Solé-Boldo L, Quick S, Steiger S, Przybilla MJ, Bauer K, Baumann A, Hemmer S, Rehnitz C, Lückerath C, Sachpekidis C, Mechtersheimer G, Haberkorn U, Dimitrakopoulou-Strauss A, Reichert P, Barlogie B, Müller-Tidow C, Goldschmidt H, Hillengass J, Rasche L, Haas SF, van Rhee F, Rippe K, Raab MS, Sauer S, Weinhold N. John L, et al. Among authors: sachpekidis c. Nat Commun. 2023 Aug 17;14(1):5011. doi: 10.1038/s41467-023-40584-4. Nat Commun. 2023. PMID: 37591845 Free PMC article.

3

Positron Emission Tomography-Based Immunoimaging for Cancer Patient Stratification: Toward a More Holistic Approach.

Dimitrakopoulou-Strauss A, Sachpekidis C, Hassel JC, Christopoulos P. Dimitrakopoulou-Strauss A, et al. Among authors: sachpekidis c. Cancer Biother Radiopharm. 2023 May;38(4):225-231. doi: 10.1089/cbr.2022.0067. Epub 2022 Dec 23. Cancer Biother Radiopharm. 2023. PMID: 36961434

4

The prognostic value of [¹⁸F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria.

Sachpekidis C, Weru V, Kopp-Schneider A, Hassel JC, Dimitrakopoulou-Strauss A. Sachpekidis C, et al. Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2699-2714. doi: 10.1007/s00259-023-06243-y. Epub 2023 Apr 26. Eur J Nucl Med Mol Imaging. 2023. PMID: 37099131 Free PMC article.

5

A decision support system for the identification of metastases of Metastatic Melanoma using whole-body FDG PET/CT images.

Vagenas TP, Economopoulos TL, Sachpekidis C, Dimitrakopoulou-Strauss A, Pan L, Provata A, Matsopoulos GK. Vagenas TP, et al. Among authors: sachpekidis c. IEEE J Biomed Health Inform. 2022 Dec 19;PP. doi: 10.1109/JBHI.2022.3230060. Online ahead of print. IEEE J Biomed Health Inform. 2022. PMID: 37015600

6

Application of the long axial field-of-view PET/CT with low-dose [¹⁸F]FDG in melanoma.

Sachpekidis C, Pan L, Kopp-Schneider A, Weru V, Hassel JC, Dimitrakopoulou-Strauss A. Sachpekidis C, et al. Eur J Nucl Med Mol Imaging. 2023 Mar;50(4):1158-1167. doi: 10.1007/s00259-022-06070-7. Epub 2022 Dec 7. Eur J Nucl Med Mol Imaging. 2023. PMID: 36474125 Free PMC article.

7

Can physiologic colonic [¹⁸F]FDG uptake in PET/CT imaging predict response to immunotherapy in metastatic melanoma?

Sachpekidis C, Stein-Thoeringer CK, Kopp-Schneider A, Weru V, Dimitrakopoulou-Strauss A, Hassel JC. Sachpekidis C, et al. Eur J Nucl Med Mol Imaging. 2023 Oct;50(12):3709-3722. doi: 10.1007/s00259-023-06327-9. Epub 2023 Jul 15. Eur J Nucl Med Mol Imaging. 2023. PMID: 37452874 Free PMC article.

8

Unusual Extramedullary Manifestation in Multiple Myeloma: Bilateral Synchronous Testicular Infiltration.

Strauss D, Sachpekidis C, Dapunt U, Goldschmidt H, Dimitrakopoulou-Strauss A. Strauss D, et al. Among authors: sachpekidis c. Clin Nucl Med. 2023 Feb 1;48(2):e76-e77. doi: 10.1097/RLU.0000000000004496. Epub 2022 Nov 18. Clin Nucl Med. 2023. PMID: 36399719

9

Application of an artificial intelligence-based tool in [¹⁸F]FDG PET/CT for the assessment of bone marrow involvement in multiple myeloma.

Sachpekidis C, Enqvist O, Ulén J, Kopp-Schneider A, Pan L, Jauch A, Hajiyianni M, John L, Weinhold N, Sauer S, Goldschmidt H, Edenbrandt L, Dimitrakopoulou-Strauss A. Sachpekidis C, et al. Eur J Nucl Med Mol Imaging. 2023 Oct;50(12):3697-3708. doi: 10.1007/s00259-023-06339-5. Epub 2023 Jul 26. Eur J Nucl Med Mol Imaging. 2023. PMID: 37493665 Free PMC article. Clinical Trial.

10

A comparative assessment of intra- and inter- observer repeatability of three widely used software packages for the quantification of defect size in stress myocardial perfusion scintigraphy.

Sachpekidis C, Kopp-Schneider A, Sachpekidis V, Moralidis E. Sachpekidis C, et al. Among authors: sachpekidis v. Hell J Nucl Med. 2022 Sep-Dec;25(3):274-284. doi: 10.1967/s002449912516. Epub 2022 Dec 14. Hell J Nucl Med. 2022. PMID: 36507884 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

114 results

Search Page

Filters